Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 5/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.51 |
| ▸ | GSK3A | P49840 | 2/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4370987 | 0.91 | HINT1 (0.55) | HINT1NT5EPOLBTGM2STING1 | |
| SCHEMBL13833321 | 0.89 | ADORA3 (0.53) | HINT1NT5EPOLBTGM2STING1 | |
| SCHEMBL12031117 | 0.89 | ADORA3 (0.53) | HINT1NT5EPOLBTGM2STING1 | |
| SCHEMBL16695880 | 0.89 | ADORA3 (0.53) | HINT1NT5EPOLBTGM2STING1 | |
| SCHEMBL4323450 | 0.89 | ADORA3 (0.53) | HINT1NT5EPOLBTGM2STING1 | |
| SCHEMBL18759056 | 0.89 | ADORA3 (0.53) | HINT1NT5EPOLBTGM2STING1 | |
| SCHEMBL9200583 | 0.89 | ADORA3 (0.53) | HINT1NT5EPOLBTGM2STING1 | |
| SCHEMBL98906 | 0.89 | ADORA3 (0.53) | HINT1NT5EPOLBTGM2STING1 | |
| SCHEMBL98907 | 0.89 | ADORA3 (0.53) | HINT1NT5EPOLBTGM2STING1 | |
| SCHEMBL11929887 | 0.89 | ADORA3 (0.53) | HINT1NT5EPOLBTGM2STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009517350-A | — | — | 2009-04-30 | — | — | JP | claimed |
| US-20090017106-A1 | ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTENE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2009-01-15 | — | — | US | claimed |
| EP-1973571-A1 | NEW ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTEINE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2008-10-01 | — | — | EP | claimed |
| WO-2007059931-A1 | NEW ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTEINE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2007-05-31 | — | — | WO | claimed |
| US-8119689-B2 | Adjuvants on the basis of bisacyloxypropylcystene conjugates and derivatives and their uses in pharmaceutical compositions | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20090017106-A1 | ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTENE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2009-01-15 | — | — | US | disclosed |
| EP-1973571-A1 | NEW ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTEINE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007059931-A1 | NEW ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTEINE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017106-A1 | ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTENE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | CYSLTR2, CYSLTR1, GSTO1 | HINT1 2374/4885NT5E 994/4885POLB 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.